Ramelteon

Last updated

Ramelteon
Ramelteon skeletal formula.svg
Ramelteon ball-and-stick model.png
Clinical data
Trade names Rozerem, others
Other namesTAK-375
AHFS/Drugs.com Monograph
MedlinePlus a605038
License data
Dependence
liability 		Low [1]
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 1.8% [3]
Protein binding 82% (mainly albumin) [3]
Metabolism Liver (CYP1A2 major, CYP2C and CYP3A4 minor) [3]
Metabolites M-II (active metabolite) [3]
Elimination half-life Ramelteon: 1–2.6 hours [3]
M-II: 2–5 hours [3] [4]
Excretion Kidney: 84% [3]
Feces: 4% [3]
Identifiers
  • (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]
    furan-8-yl)ethyl]propionamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.215.666 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C16H21NO2
Molar mass 259.349 g·mol−1
3D model (JSmol)
  • CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3
  • InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m1/s1 Yes check.svgY
  • Key:YLXDSYKOBKBWJQ-GFCCVEGCSA-N Yes check.svgY
   (verify)

Ramelteon, sold under the brand name Rozerem among others, is a melatonin agonist medication which is used in the treatment of insomnia. [3] [5] It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset. [3] It reduces the time taken to fall asleep, but the degree of clinical benefit is small. [6] The medication is approved for long-term use. [3] Ramelteon is taken by mouth. [3]

Contents

Side effects of ramelteon include somnolence, dizziness, fatigue, nausea, exacerbated insomnia, and changes in hormone levels. [3] Ramelteon is an analogue of melatonin and is a selective agonist of the melatonin MT1 and MT2 receptors. [3] The half-life and duration of ramelteon are much longer than those of melatonin. [7] Ramelteon is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. [3] [8]

Ramelteon was first described in 2002 [9] and was approved for medical use in 2005. [10] Unlike certain other sleep medications, ramelteon is not a controlled substance [ contradictory ] and has no known potential for misuse. [3]

Medical uses

Insomnia

Ramelteon is approved for the treatment of insomnia characterized by difficulty with sleep onset in adults. [3] [5] In regulatory clinical trials, it was found to significantly reduce latency to persistent sleep (LPS). [3] A 2009 pooled analysis of four clinical trials found that ramelteon at a dose of 8 mg reduced sleep onset by 13 minutes (30% decrease) relative to placebo on the first and second nights of use. [11] Subsequent meta-analyses of longer-duration use have found that ramelteon decreases subjective sleep latency by about 4 to 7 minutes. [6] [12] Meta-analyses are mixed on whether ramelteon increases total sleep time. [12] [6] Ramelteon also improves sleep quality (SMD Tooltip standardized mean difference –0.074, 95% CI Tooltip confidence interval –0.13 to –0.02) and sleep efficiency. [6] The clinical improvement in insomnia with ramelteon is small and of questionable benefit. [6] [8]

Ramelteon is approved in the United States but was not approved in the European Union owing to concerns that it lacked effectiveness. [8] The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) noted that ramelteon had only been found to improve sleep onset and not other sleep outcomes, only one of three clinical trials actually found that it improved sleep onset, and that the improvement in sleep onset was too small to be clinically meaningful. [8] The CHMP also noted that the long-term effectiveness of ramelteon had not been demonstrated. [8]

The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommended the use of ramelteon in the treatment of sleep-onset insomnia. [13] It rated the recommendation as weak and the quality of evidence as very low but concluded that the potential benefits outweighed the potential harms. [13] The guidelines found that ramelteon reduces sleep latency by 9 minutes (95% CI Tooltip confidence interval 6–12 minutes) but does not improve sleep quality. [13] In contrast to ramelteon, the guidelines did not recommend the use of melatonin. [13]

Circadian rhythm sleep disorders

Melatonin receptor agonists like melatonin and tasimelteon are considered to be effective in regulating sleep–wake cycles and in the treatment of circadian rhythm sleep disorders like delayed sleep phase disorder. [14] [15] Ramelteon has been assessed in only a few studies in the treatment of circadian rhythm sleep disorders, including jet lag disorder, shift work disorder, and non-24-hour sleep–wake disorder. [14] These studies have been of varying quality and their findings in terms of effectiveness have been mixed. [14] Ramelteon is approved only for treatment of insomnia and is not approved for treatment of circadian rhythm sleep disorders. [14] [16] It was previously under development for treatment of circadian rhythm sleep disorders, but development for these indications was discontinued. [16]

Other uses

Delirium

A systematic review, published in 2014, concluded "ramelteon was found to be beneficial in preventing delirium in medically ill individuals when compared to placebo." [17] A 2022 systematic review and meta-analysis found that the combination of ramelteon and the orexin receptor antagonist suvorexant may reduce the incidence of delirium in adults hospitalized patients whereas suvorexant alone was ineffective. [18]

Bipolar disorder

Ramelteon has received attention in psychiatry as a possible add-on treatment for mania in bipolar disorder. [19] However, to date, the scarce available evidence fails to support the clinical utility of ramelteon and other melatonin receptor agonists such as melatonin for mania. [19]

Available forms

Ramelteon is available in the form of 8 mg oral film-coated tablets. [3]

Contraindications

Ramelteon is not recommended for use in people with severe sleep apnea. [3]

Adverse effects

Side effects of ramelteon include somnolence (3% vs. 2% for placebo), fatigue (3% vs. 2% for placebo), dizziness (4% vs. 3% for placebo), nausea (3% vs. 2% for placebo), and exacerbated insomnia (3% vs. 2% for placebo). [3] Overall, side effects occurred in 6% with ramelteon and 2% with placebo in clinical trials. [3] Side effects leading to discontinuation occurred in 1% or fewer people. [3] Rarely, anaphylactic reactions, abnormal thinking, and worsening of depression or suicidal thinking in patients with pre-existing depression may occur with ramelteon. [3] Ramelteon has been found to slightly increase prolactin levels in women (+34% vs. –4% with placebo) but not in men and to decrease free testosterone levels (by 3–6% in younger men and by 13–18% in older men). [3] [20] [21]

Ramelteon has not been shown to produce dependence and has shown no potential for abuse. [3] The withdrawal and rebound insomnia that is typical with GABAA receptor positive modulators like benzodiazepines and Z-drugs is not present in ramelteon. [3]

Increased incidence of liver and testicular tumors have been observed with ramelteon in rodents but only at doses equivalent to at least 20 times greater than the recommended dose in humans. [3]

Overdose

Ramelteon has been assessed at doses of up to 64 mg in clinical studies. [3]

Interactions

Ramelteon has been evaluated for potential drug interactions with the following medications and showed no significant effects: omeprazole, theophylline, dextromethorphan, and midazolam, digoxin and warfarin. There were no clinically meaningful effects when ramelteon was coadministered with any of these drugs.[ medical citation needed ]

A drug interaction study showed that there were no clinically meaningful effects or an increase in adverse events when ramelteon and the SSRI Prozac (fluoxetine) were coadministered. When coadministered with ramelteon, fluvoxamine (strong CYP1A2 inhibitor) increased AUC approximately 190-fold, and the Cmax increased approximately 70-fold, compared to ramelteon administered alone. Ramelteon and fluvoxamine should not be coadministered. [3]

Ramelteon has significant drug–drug interaction with the following drugs: amiodarone , ciprofloxacin , fluvoxamine , ticlopidine.

Ramelteon should be administered with caution in patients taking other CYP1A2 inhibitors, strong CYP3A4 inhibitors such as ketoconazole, and strong CYP2C9 inhibitors such as fluconazole. [3]

Efficacy may be reduced when ramelteon is used in combination with potent CYP enzyme inducers such as rifampin, since ramelteon concentrations may be decreased.[ medical citation needed ]

Pharmacology

Pharmacodynamics

Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the non-human MT3 receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT1 or MT2 receptors, and high selectivity for human MT1 and MT2 receptors compared to the non-human MT3 receptor. [22] The affinity of ramelteon for the MT1 and MT2 receptors is 3 to 16 times higher than that of melatonin. [8] Ramelteon has 8-fold higher affinity for the MT1 receptor over the MT2 receptor. [8] The binding profile of ramelteon distinguishes it from melatonin, tasimelteon, and agomelatine. [8] [23] Remelteon has a clinically irrelevant affinity for the serotonin 5-HT1A receptor (Ki = 5.6 μM). [24]

The major metabolite of ramelteon, M-II, is active and has approximately one-tenth and one-fifth the binding affinity of the parent molecule for the human MT1 and MT2 receptors, respectively, and is 17- to 25-fold less potent than ramelteon in in vitro functional assays. Although the potency of M-II at MT1 and MT2 receptors is lower than the parent drug, M-II circulates at higher concentrations than the parent producing 20- to 100-fold greater mean systemic exposure when compared to ramelteon. M-II has weak affinity for the serotonin 5-HT2B receptor, but no appreciable affinity for other receptors or enzymes. Similar to ramelteon, M-II does not interfere with the activity of a number of endogenous enzymes.[ medical citation needed ]

Ramelteon has no appreciable affinity for the GABA receptors or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline, acetylcholine, and opioids. Ramelteon also does not interfere with the activity of a number of selected enzymes in a standard panel.[ medical citation needed ]

Mechanism of action

The activity of ramelteon at the MT1 and MT2 receptors in the suprachiasmatic nucleus of the hypothalamus is believed to contribute to its sleep-promoting properties, as these receptors, acted upon by endogenous melatonin, are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep–wake cycle.

Pharmacokinetics

Absorption

The total absorption of ramelteon is 84% while its oral bioavailability is 1.8%. [3] The low bioavailability of ramelteon is due to extensive first-pass metabolism. [3] Ramelteon has a higher lipophilicity than melatonin and thus permeates more easily into tissue. [24] The absorption of ramelteon is rapid, with peak levels being reached after approximately 0.75 hours (range 0.5–1.5 hours). [3] Food increases peak concentrations of ramelteon by 22% and overall exposure by 31% and delays the time to peak levels by approximately 0.75 hours. [3] The pharmacokinetics of ramelteon are linear across a dose range of 4 to 64 mg. [3] There is substantial interindividual variability in the peak concentrations and area-under-the-curve levels of ramelteon which is consistent with high first-pass metabolism. [3]

Distribution

The volume of distribution of ramelteon is 73.6 L, which suggests substantial tissue distribution. [3] The plasma protein binding of ramelteon is 82% independently of concentration. [3] Ramelteon is primarily bound to albumin (70%). [3] The medication is not selectively distributed to red blood cells. [3]

Metabolism

Ramelteon is metabolized in the liver primarily by oxidation via hydroxylation and carbonylation. [3] It is also secondarily metabolized to produce glucuronide conjugates. [3] Ramelteon is metabolized mainly by CYP1A2 while CYP2C enzymes and CYP3A4 are involved to a minor extent. [3] The metabolites of ramelteon include M-I, M-II, M-III, and M-IV. [3] Exposure to M-II is approximately 20- to 100-fold higher than to ramelteon. [3]

Elimination

Ramelteon is excreted 84% in urine and 4% in feces. [3] Less than 0.1% of drug is excreted as unchanged ramelteon. [3] Elimination of ramelteon is essentially complete by 96 hours following a single dose. [3]

The elimination half-life of ramelteon is 1 to 2.6 hours while the half-life of M-II, the major active metabolite of ramelteon, is 2 to 5 hours. [3] [7] The half-lives of ramelteon and M-II are substantially longer than that of melatonin, which has a half-life in the range of 20 to 45 minutes. [7] Levels of ramelteon and its metabolites at or below the limit of detectability within 24 hours following a dose. [3]

Special populations

Peak levels of ramelteon and overall exposure are about 86% and 97% higher, respectively, in elderly adults compared to younger adults. [3] Conversely, peak levels of M-II are 13% and overall exposure 30% higher in elderly adults than in younger adults. [3] The elimination half-life of ramelteon is 2.6 hours in elderly adults. [3]

History

Ramelteon was first described in the medical literature in 2002. [9] It was approved for use in the United States in July 2005. [10]

Society and culture

Ramelteon has no potential for abuse or drug dependence and is not a controlled substance. [25]

Research

Ramelteon, along with other melatonin receptor agonists like melatonin, has been repurposed in clinical trials as an adjunctive treatment for acute manic episodes in subjects with bipolar disorder. [19] Nonetheless, meta-analytic evidence is based on very few trials and does not allow supporting the use of melatonin receptor agonists as adjunctive options for mania in clinical practice, although the small sample size do not allow ruling out their beneficial effect. [19]

Related Research Articles

<span class="mw-page-title-main">Hypnotic</span> Drug whose use induces sleep

Hypnotic, or soporific drugs, commonly known as sleeping pills, are a class of psychoactive drugs whose primary function is to induce sleep and to treat insomnia (sleeplessness).

<span class="mw-page-title-main">Insomnia</span> Disorder causing trouble with sleeping

Insomnia, also known as sleeplessness, is a sleep disorder where people have trouble sleeping. They may have difficulty falling asleep, or staying asleep for as long as desired. Insomnia is typically followed by daytime sleepiness, low energy, irritability, and a depressed mood. It may result in an increased risk of accidents of all kinds as well as problems focusing and learning. Insomnia can be short term, lasting for days or weeks, or long term, lasting more than a month. The concept of the word insomnia has two possibilities: insomnia disorder (ID) and insomnia symptoms, and many abstracts of randomized controlled trials and systematic reviews often underreport on which of these two possibilities the word insomnia refers to.

<span class="mw-page-title-main">Delayed sleep phase disorder</span> Chronic mismatch between a persons normal daily rhythm, compared to other people and societal norms

Delayed sleep phase disorder (DSPD), more often known as delayed sleep phase syndrome and also as delayed sleep–wake phase disorder, is the delaying of a person's circadian rhythm compared to those of societal norms. The disorder affects the timing of biological rhythms including sleep, peak period of alertness, core body temperature, and hormonal cycles.

<span class="mw-page-title-main">Zolpidem</span> Hypnotic medication

Zolpidem, sold under the brand name Ambien among others, is a medication primarily used for the short-term treatment of sleeping problems. Guidelines recommend that it be used only after cognitive behavioral therapy for insomnia and behavioral changes, such as sleep hygiene, have been tried. It decreases the time to sleep onset by about fifteen minutes and at larger doses helps people stay asleep longer. It is taken by mouth and is available in conventional tablets, sublingual tablets, or oral spray.

Non-24-hour sleep–wake disorder is one of several chronic circadian rhythm sleep disorders (CRSDs). It is defined as a "chronic steady pattern comprising [...] daily delays in sleep onset and wake times in an individual living in a society". Symptoms result when the non-entrained (free-running) endogenous circadian rhythm drifts out of alignment with the light–dark cycle in nature. Although this sleep disorder is more common in blind people, affecting up to 70% of the totally blind, it can also affect sighted people. Non-24 may also be comorbid with bipolar disorder, depression, and traumatic brain injury. The American Academy of Sleep Medicine (AASM) has provided CRSD guidelines since 2007 with the latest update released in 2015.

<span class="mw-page-title-main">Eszopiclone</span> Hypnotic medication

Eszopiclone, sold under the brand name Lunesta among others, is a medication used in the treatment of insomnia. Evidence supports slight to moderate benefit up to six months. It is taken by mouth.

<span class="mw-page-title-main">Nonbenzodiazepine</span> Class of psychoactive drugs

Nonbenzodiazepines, sometimes referred to colloquially as Z-drugs, are a class of psychoactive drugs that are benzodiazepine-like in uses, such as for treating insomnia and anxiety.

<span class="mw-page-title-main">Agomelatine</span> Atypical antidepressant classified primarily as a melatonin receptor agonist

Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but fewer discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants.

Melatonin receptors are G protein-coupled receptors (GPCR) which bind melatonin. Three types of melatonin receptors have been cloned. The MT1 (or Mel1A or MTNR1A) and MT2 (or Mel1B or MTNR1B) receptor subtypes are present in humans and other mammals, while an additional melatonin receptor subtype MT3 (or Mel1C or MTNR1C) has been identified in amphibia and birds. The receptors are crucial in the signal cascade of melatonin. In the field of chronobiology, melatonin has been found to be a key player in the synchrony of biological clocks. Melatonin secretion by the pineal gland has circadian rhythmicity regulated by the suprachiasmatic nucleus (SCN) found in the brain. The SCN functions as the timing regulator for melatonin; melatonin then follows a feedback loop to decrease SCN neuronal firing. The receptors MT1 and MT2 control this process. Melatonin receptors are found throughout the body in places such as the brain, the retina of the eye, the cardiovascular system, the liver and gallbladder, the colon, the skin, the kidneys, and many others. In 2019, X-ray crystal and cryo-EM structures of MT1 and MT2 were reported.

<span class="mw-page-title-main">Tasimelteon</span> Wakefulness medication

Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA) in January 2014, for the treatment of non-24-hour sleep–wake disorder. In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults, but not in the case of non-24 in sighted people.

<span class="mw-page-title-main">Melatonin receptor agonist</span>

Melatonin receptor agonists are analogues of melatonin that bind to and activate the melatonin receptor. Agonists of the melatonin receptor have a number of therapeutic applications including treatment of sleep disorders and depression. The discovery and development of melatonin receptor agonists was motivated by the need for more potent analogues than melatonin, with better pharmacokinetics and longer half-lives. Melatonin receptor agonists were developed with the melatonin structure as a model.

<span class="mw-page-title-main">Suvorexant</span> Medication used to treat insomnia

Suvorexant, sold under the brand name Belsomra, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. Suvorexant helps with falling asleep faster, sleeping longer, being awake less in the middle of the night, and having better quality of sleep. Its effectiveness is modest, and is similar to that of other orexin antagonists, but is lower than that of benzodiazepines and Z-drugs. Suvorexant is taken by mouth.

An orexin receptor antagonist, or orexin antagonist, is a drug that inhibits the effect of orexin by acting as a receptor antagonist of one (selective orexin receptor antagonist or SORA) or both (dual orexin receptor antagonis or DORA) of the orexin receptors, OX1 and OX2. Medical applications include treatment of sleep disorders such as insomnia.

<span class="mw-page-title-main">TIK-301</span> Chemical compound

TIK-301 (LY-156735) is an agonist for the melatonin receptors MT1 and MT2 that is under development for the treatment of insomnia and other sleep disorders. Its agonist action on MT1 and MT2 receptors in the suprachiasmatic nucleus in the brain enables its action as a chronobiotic. It is in the same class of melatonin receptor agonists as ramelteon and tasimelteon.

<span class="mw-page-title-main">Piromelatine</span> Chemical compound

Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease.

<span class="mw-page-title-main">Lemborexant</span> Chemical compound

Lemborexant, sold under the brand name Dayvigo, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. The medication is taken by mouth.

<span class="mw-page-title-main">Daridorexant</span> Medication used to treat insomnia

Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth.

<span class="mw-page-title-main">Melatonin as a medication and supplement</span> Supplement and medication used to treat sleep disorders

Melatonin is a dietary supplement and medication as well as naturally occurring hormone. As a hormone, melatonin is released by the pineal gland and is involved in sleep–wake cycles. As a supplement, it is often used for the attempted short-term treatment of disrupted sleep patterns, such as from jet lag or shift work, and is typically taken orally. Evidence of its benefit for this use, however, is not strong. A 2017 review found that sleep onset occurred six minutes faster with use, but found no change in total time asleep.

Gabriella Gobbi is an Italo-Canadian psychiatrist and neuroscientist whose research explores novel treatments for mental health disorders. Gobbi is a professor at McGill University's Department of Psychiatry and a Canada Research Chair in Therapeutics for Mental Health.

<span class="mw-page-title-main">Somnifacient</span> Class of medications that induce sleep

Somnifacient, also known as sedatives or sleeping pills, is a class of medications that induces sleep. It is mainly used for treatment of insomnia. Examples of somnifacients include benzodiazepines, barbiturates and antihistamines.

References

  1. ↑ Kim, HK; Yang, KI (December 2022). "Melatonin and melatonergic drugs in sleep disorders". Translational and Clinical Pharmacology. 30 (4): 163–171. doi: 10.12793/tcp.2022.30.e21 . PMC   9810491 . PMID   36632077.
  2. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 "Rozerem- ramelteon tablet, film coated". DailyMed. 28 December 2018. Retrieved 13 April 2020.
  4. ↑ Karim A, Tolbert D, Cao C (February 2006). "Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia". Journal of Clinical Pharmacology. 46 (2): 140–148. doi:10.1177/0091270005283461. PMID   16432265. S2CID   38171735.
  5. 1 2 Neubauer DN (February 2008). "A review of ramelteon in the treatment of sleep disorders". Neuropsychiatric Disease and Treatment. 4 (1): 69–79. doi: 10.2147/ndt.s483 . PMC   2515902 . PMID   18728808.
  6. 1 2 3 4 5 Kuriyama A, Honda M, Hayashino Y (April 2014). "Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis". Sleep Medicine. 15 (4): 385–392. doi:10.1016/j.sleep.2013.11.788. PMID   24656909.
  7. 1 2 3 Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP (2008). "Melatonergic drugs in clinical practice". Arzneimittel-Forschung. 58 (1): 1–10. doi:10.1055/s-0031-1296459. PMID   18368944. S2CID   38857779.
  8. 1 2 3 4 5 6 7 8 Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery". Pharmacological Reviews. 70 (2): 197–245. doi: 10.1124/pr.117.014381 . PMID   29487083. S2CID   3578916.
  9. 1 2 Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y, et al. (September 2002). "Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists". Journal of Medicinal Chemistry. 45 (19): 4222–4239. doi:10.1021/jm0201159. PMID   12213063.
  10. 1 2 "Drug Approval Package: Rozerem (Ramelteon) NDA #021782". U.S. Food and Drug Administration (FDA). 20 October 2005. Retrieved 13 April 2020.
  11. ↑ Wang-Weigand S, McCue M, Ogrinc F, Mini L (May 2009). "Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis". Current Medical Research and Opinion. 25 (5): 1209–1213. doi:10.1185/03007990902858527. PMID   19327100. S2CID   72050626.
  12. 1 2 Liu J, Wang LN (September 2012). "Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis". International Journal of Clinical Practice. 66 (9): 867–873. doi: 10.1111/j.1742-1241.2012.02987.x . PMID   22897464. S2CID   33979712.
  13. 1 2 3 4 Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (February 2017). "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline". Journal of Clinical Sleep Medicine. 13 (2): 307–349. doi:10.5664/jcsm.6470. PMC   5263087 . PMID   27998379.
  14. 1 2 3 4 Williams WP, McLin DE, Dressman MA, Neubauer DN (September 2016). "Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders". Pharmacotherapy. 36 (9): 1028–1041. doi:10.1002/phar.1822. PMC   5108473 . PMID   27500861.
  15. ↑ Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL (August 2017). "Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders". Sleep Medicine Reviews. 34: 10–22. doi:10.1016/j.smrv.2016.06.005. hdl: 20.500.11820/0e890bda-4b1d-4786-a907-a03b1580fd07 . PMID   28648359.
  16. 1 2 "Ramelteon - Takeda". AdisInsight. Springer Nature Switzerland AG.
  17. ↑ Chakraborti D, Tampi DJ, Tampi RR (March 2015). "Melatonin and melatonin agonist for delirium in the elderly patients". American Journal of Alzheimer's Disease and Other Dementias. 30 (2): 119–129. doi: 10.1177/1533317514539379 . PMID   24946785. S2CID   34291546.
  18. ↑ Tian Y, Qin Z, Han Y (March 2022). "Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis". Psychogeriatrics. 22 (2): 259–268. doi:10.1111/psyg.12792. PMID   34881812. S2CID   245076331.
  19. 1 2 3 4 Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, Carrà G (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID   34509090. S2CID   237485915.
  20. ↑ Richardson G, Wang-Weigand S (March 2009). "Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia". Human Psychopharmacology. 24 (2): 103–111. doi:10.1002/hup.993. PMID   19090503. S2CID   23831933.
  21. ↑ Richardson GS, Zammit G, Wang-Weigand S, Zhang J (April 2009). "Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study". The Journal of Clinical Psychiatry. 70 (4): 467–476. doi:10.4088/jcp.07m03834. PMID   19284927.
  22. ↑ Owen RT (April 2006). "Ramelteon: profile of a new sleep-promoting medication". Drugs of Today. 42 (4): 255–263. doi:10.1358/dot.2006.42.4.970842. PMID   16703122.
  23. ↑ Lavedan C, Forsberg M, Gentile AJ (April 2015). "Tasimelteon: a selective and unique receptor binding profile". Neuropharmacology. 91: 142–147. doi: 10.1016/j.neuropharm.2014.12.004 . PMID   25534555. S2CID   12767672.
  24. 1 2 Pandi-Perumal SR, Spence DW, Verster JC, Srinivasan V, Brown GM, Cardinali DP, Hardeland R (January 2011). "Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications". Journal of Central Nervous System Disease. 3: 51–65. doi:10.4137/JCNSD.S1611. PMC   3663615 . PMID   23861638.
  25. ↑ McGechan A, Wellington K (2005). "Ramelteon". CNS Drugs. 19 (12): 1057–65, discussion 1066–7. doi:10.2165/00023210-200519120-00007. PMID   16332146. S2CID   262241187.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.